Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy.
Jeffrey C ThompsonErica L CarpenterBenjamin A SilvaJamie RosensteinAustin L ChienKatie QuinnCarin R EspenschiedAllysia MakLesli A KiedrowskiMartina LefterovaRebecca J NagySharyn I KatzStephanie S YeeTaylor A BlackAditi P SinghChristine A CiunciJoshua M BaumlRoger B CohenCorey J LangerCharu AggarwalPublished in: JCO precision oncology (2021)
Molecular response assessment using circulating tumor DNA may serve as a noninvasive, on-therapy predictor of response to pembrolizumab-based therapy in addition to standard of care imaging in mNSCLC. This strategy requires validation in independent prospective studies.
Keyphrases
- circulating tumor
- cell free
- circulating tumor cells
- advanced non small cell lung cancer
- healthcare
- small cell lung cancer
- single molecule
- palliative care
- high resolution
- stem cells
- mass spectrometry
- bone marrow
- genome wide
- copy number
- cell therapy
- pain management
- health insurance
- brain metastases
- case control
- affordable care act
- replacement therapy